In general it remains unclear if omitting upfront radiotherapy due to the younger age in patients with PB-MYC/FOXR2 and PB-RB1 tumors alone is responsible for the worse outcome, or if the tumor biology of these two subtypes has a prognostic impact and leads to the inferior survival compared to patients with PB-miRNA tumors. Here, FOXR2 is linked to neoplasm.